Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX-8177 in advanced solid tumors
NCT07310134Phase 1Recruiting
- Sponsor
- Zenshine Pharmaceuticals Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ZX-8177 in solid tumor (advanced stage), sponsored by Zenshine Pharmaceuticals Co., Ltd. Primary endpoints: Participant Safety and Dose-Limiting Toxicity. Started Dec 2025; status: recruiting.
02
Drugs
ZX-8177
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07310134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07310134.